FibroBiologics Inc. (NASDAQ:FBLG) Stock Has Average Price Target of $73.00

FibroBiologics Inc. (NASDAQ:FBLG) has earned a consensus recommendation of “Reduce” from the five ratings firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $73.00.

Several research analysts have weighed in on FBLG shares. Deutsche Bank Aktiengesellschaft downgraded shares of FibroBiologics to an “underperform” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, September 4th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective (down from $8.00) on shares of FibroBiologics in a research note on Tuesday, August 4th. Finally, Wall Street Zen raised FibroBiologics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th.

FibroBiologics Stock Up 2.2%

Shares of NASDAQ:FBLG opened at $1.39 on Wednesday. The firm’s 50 day moving average price is $1.24 and its 200-day moving average price is $1.65. FibroBiologics has a twelve month low of $0.62 and a twelve month high of $12.40. The stock has a market capitalization of $9.26 million, a PE ratio of -0.27 and a beta of 1.65.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings data on Friday, July 31st. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.27. Analysts expect that FibroBiologics will post -3 earnings per share for the current fiscal year.

FibroBiologics Company Profile

FibroBiologics, Inc is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. The company’s research focuses on fibroblasts, a type of cell involved in tissue maintenance and repair, and the biologically active factors and extracellular vesicles that these cells produce.

FibroBiologics is developing a proprietary platform intended to generate therapeutic products from fibroblast-derived cells and their secretions. Its pipeline is aimed at conditions associated with tissue damage, inflammation, and impaired regeneration, including multiple sclerosis, psoriasis, and degenerative disc disease.